

# Global Autism Drugs and Companies Pipeline Review H2 2016

*Autism Treatment Pipeline Review H2 2016*

PUNE, INDIA, August 30, 2016

/EINPresswire.com/ --

## Summary

'[Autism](#) - Pipeline Review, H2 2016', provides an overview of the Autism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Autism and features dormant and discontinued projects.



Complete report details @ <https://www.wiseguyreports.com/reports/619301-autism-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain

competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619301-autism-pipeline-review-h2-2016>

### Scope

- The report provides a snapshot of the global therapeutic landscape of Autism
- The report reviews pipeline therapeutics for Autism by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Autism therapeutics and enlists all their major and minor projects
- The report assesses Autism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Autism

### Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Autism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619301-autism-pipeline-review-h2-2016>

Key points in table of content

Table of Contents

Table of Contents	2
List of Tables	7
List of Figures	8
Introduction	9
Global Markets Direct Report Coverage	9
Autism Overview	10
Therapeutics Development	11
Pipeline Products for Autism - Overview	11
Pipeline Products for Autism - Comparative Analysis	12
Autism - Therapeutics under Development by Companies	13
Autism - Therapeutics under Investigation by Universities/Institutes	16
Autism - Pipeline Products Glance	17
Late Stage Products	17
Clinical Stage Products	18
Early Stage Products	19
Unknown Stage Products	20
Autism - Products under Development by Companies	21
Autism - Products under Investigation by Universities/Institutes	23
Autism - Companies Involved in Therapeutics Development	24
Addex Therapeutics Ltd	24
Aequus Pharmaceuticals Inc.	25
AgeneBio Inc.	26
APeT Holding BV	27
BioCrea GmbH	28
BrainStorm Cell Therapeutics Inc.	29
Cellceutix Corporation	30
Confluence Pharmaceuticals LLC	31
Coronis Partners Ltd.	32
Curemark, LLC	33
F. Hoffmann-La Roche Ltd.	34
GW Pharmaceuticals Plc	35
Heptares Therapeutics Limited	36
Intra-Cellular Therapies, Inc.	37
MedDay SA	38
Omeros Corporation	39
Otsuka Holdings Co., Ltd.	40
Retrophin Inc.	41
Saniona AB	42
Sumitomo Dainippon Pharma Co., Ltd.	43
Autism - Therapeutics Assessment	44
Assessment by Monotherapy Products	44
Assessment by Combination Products	45
Assessment by Target	46

Assessment by Mechanism of Action 49  
Assessment by Route of Administration 52  
Assessment by Molecule Type 54  
Drug Profiles 56  
(dextromethorphan + quinidine sulfate) - Drug Profile 56  
Product Description 56  
Mechanism Of Action 56  
R&D Progress 56  
acamprosate calcium - Drug Profile 61  
Product Description 61  
Mechanism Of Action 61  
R&D Progress 61  
ACT-01 - Drug Profile 62  
Product Description 62  
Mechanism Of Action 62  
R&D Progress 62  
ADX-71441 - Drug Profile 63  
Product Description 63  
Mechanism Of Action 63  
R&D Progress 63  
ADX-88178 - Drug Profile 66  
Product Description 66  
Mechanism Of Action 66  
R&D Progress 66  
aripiprazole - Drug Profile 68  
Product Description 68  
Mechanism Of Action 68  
R&D Progress 68  
aripiprazole - Drug Profile 72  
Product Description 72  
Mechanism Of Action 72  
R&D Progress 72  
carbetocin - Drug Profile 74  
Product Description 74  
Mechanism Of Action 74  
R&D Progress 74  
CB-0306 - Drug Profile 75  
Product Description 75  
Mechanism Of Action 75  
R&D Progress 75  
CM-AT - Drug Profile 76  
Product Description 76  
Mechanism Of Action 76

R&D Progress 76

Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Buy this report @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=619301](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619301)

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/342315752>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.